Why Did Hexo Stock Drop 10% on Tuesday?

Among cannabis stocks, Hexo (TSX:HEXO)(NASDAQ:HEXO) may top the list as biggest loser of 2021 and perhaps even 2022 with the way it’s going.

| More on:

There’s really only one word that can describe what happened to Hexo (TSX:HEXO)(NASDAQ:HEXO) on Tuesday: ouch. Shares fell to 52-week lows at $0.73 per share, down 10% at its lowest point.

What happened?

The small-cap stock continued to drop since announcing its losses late last year and even since appointing a new chief financial officer at the beginning of 2022. Hexo announced a loss of $116.9 million in the first quarter, along with a “new strategic plan” to reduce costs and create synergies.

That loss was a whopping 2,683% increase from the same time the year before, ahead of an overhaul of operations. It was the nail in the coffin, it seemed, since Chief Executive Officer Sebastien St-Louis and Chief Operating Officer Donald Courtney left Hexo in October.

So what?

While Hexo management has moved on, investors it seems have as well. Hexo right now looks like a loss at a time when investors aren’t looking for risk in their portfolio. The company didn’t maintain internal control over financial reporting, and that has to change.

To do this, the company will have to follow through with its plan to decrease costs as well as create acquisitions that could accelerate the company towards profitability. To do this quicker, Hexo management stated it will now focus on medical cannabis, expecting to create $50 million in synergies from recent acquisitions. This is an increase from $35 million previously announced.

Now what?

Let’s say Hexo checks all of these boxes. Is it still the cannabis company you want in your portfolio long term? Probably not. Supply and demand remain an incredible problem for cannabis companies. Meanwhile, the days of unprofitable marijuana companies should soon be over. Whether that means Hexo is purchased or collapses remains to be seen.

That being said, Hexo may also be undervalued given that it’s now at $0.73 per share. In fact, analysts still give it a consensus target price of $1.49, which is double today’s price. While that’s not that impressive, given that it traded at $14 at its 52-week high, it’s something.

Hexo stock announced its next earnings report would be Mar. 8, 2022. So, investors still have time to decide.

Fool contributor Amy Legate-Wolfe owns HEXO Corp. The Motley Fool recommends HEXO Corp.

More on Cannabis Stocks

four people hold happy emoji masks
Dividend Stocks

Wary of Mining Companies? A Lower-Risk Way to Get in on the Gold and Silver Surge

Frenco-Nevada (TSX:FNV) stock might be a wiser way to play the run in gold prices this year.

Read more »

Cannabis smoke
Cannabis Stocks

Have Cannabis Stocks Totally Gone Up in Smoke?

Let's dive into whether Canadian cannabis stocks are still investable, and what investors should make of the recent volatility in…

Read more »

Researcher works in hemp field
Cannabis Stocks

1 Undervalued Cannabis Stock to Buy and Hold Over the Next Decade

Green Thumb is a beaten-down cannabis stock that trades at a compelling valuation in September 2025.

Read more »

Researcher works in hemp field
Cannabis Stocks

Pot Stocks Rallied Hard in August: Is There More to Come?

Tilray Brands (TSX:TLRY) and the broad basket of pot stocks could heat up from here.

Read more »

Pot stocks are a riskier investment
Cannabis Stocks

Canopy Growth Stock Jumped 30% Last Month: What’s Going on?

Canopy Growth (TSX:WEED) stock is picking up traction again, making it an enticing weed play to buy on strength.

Read more »

A cannabis plant grows.
Cannabis Stocks

These Threats Facing Canopy Growth Stock Could Justify Selling it

Let's dive into whether Canopy Growth (TSX:WEED) is a top stock investors should buy right now after its recent dip…

Read more »

A person holds a small glass jar of marijuana.
Stocks for Beginners

This BioCannabis Firm Could Explode with Product Approval

This cannabis stock used to be a major name, so where does it stand now?

Read more »

Medicinal research is conducted on cannabis.
Stocks for Beginners

This TSX Health-Care Stock Is a Long-Term Buy for Patient Investors

This TSX stock continues to be one of the best long-term opportunities, if you're patient.

Read more »